Greg Friberg, M.D., serves as Executive Vice President and Chief Research & Development Officer, with responsibility for BioMarin’s discovery research, preclinical, translational and clinical programs, as well as global regulatory and medical affairs.

Prior to joining BioMarin in 2024, Greg spent 18 years at Amgen, where he served most recently as Vice President, Global Medical Affairs, Rare Disease. During his time at Amgen, Greg was responsible for advancing multiple medicines from investigational new drug application filing through late-stage development, and also served as the head of global development for the company’s hematology/oncology and bone portfolios. Before beginning his career in the biopharma industry, Greg served on the faculty of the University of Chicago.

Greg holds an AB in Biochemistry from Middlebury College and an M.D. from New York Medical College. He completed his residency in Internal Medicine at Dartmouth-Hitchcock Medical Center and his fellowship in Hematology and Oncology at the University of Chicago Medical Center.

He lives in Southern California with his wife, two sons and their animals (a cat and a dog). They enjoy traveling, musical theater and an active family life.